The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime? Comment uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Combined Chemotherapy Protocols
  • CTLA-4 Antigen
  • Melanoma

abstract

  • Ipilimumab has shown an overall survival benefit in 2 randomized phase III studies. A minority of patients achieve long-term disease control, highlighting the potential of this immunotherapeutic approach. In ongoing efforts, investigators are continuing to characterize these patients' unique clinical courses and correlate their responses with underlying mechanisms of antitumor immunity.

publication date

  • April 2012

Research

keywords

  • Comment

Identity

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-12-0409

PubMed ID

  • 22338019

Additional Document Info

start page

  • 1821

end page

  • 3

volume

  • 18

number

  • 7